Asthma Research Today is a free monthly online journal that collates and summarizes the latest research about Asthma, including details on symptoms, diagnosis, treatment, causes, medications.

Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives.

Fabbri LM, Nicolini G, Olivieri D, Papi A

Department of Respiratory Diseases, University of Modena & Reggio Emilia, Via del Pozzo 71, I-41100 Modena, Italy. fabbri.leonardo@unimore.it

BACKGROUND: Combinations of a long-acting beta(2)-agonist (LABA) and an inhaled corticosteroid (ICS) are effective and safe options in asthma management. OBJECTIVE: To review available data on a recently developed combination of beclometasone dipropionate (BDP) and formoterol (F) given via a pressurized metered-dose inhaler. METHODS: Published data on preclinical and clinical studies were reviewed. RESULTS/CONCLUSION: In the treatment of asthma, BDP/F was shown to be at least as effective and well-tolerated as other available combinations of ICS and LABA with the advantage of a better cost effectiveness, and more effective in improving asthma control than BDP and formoterol given via separate inhalers. The extra-fine BDP/F combination appears to be a valuable therapeutic option in the management of asthma.

Published 28 January 2008 in Expert Opin Pharmacother, 9(3): 479-90.
Full-text of this article is available online (may require subscription).

© 2004-2008 Asthma Research Today. All Rights Reserved.